FLUCELVAX TETRA

This brand name is authorized in Austria, Brazil, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug FLUCELVAX TETRA contains a combination of these active pharmaceutical ingredients (APIs):

1	A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022 CVR-167)
	Read more about Influenza, inactivated, surface antigen
2	A/Darwin/6/2021 (H3N2)-like strain (A/Darwin/11/2021, wild type)
	Read more about Influenza, inactivated, surface antigen
3	B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type)
	Read more about Influenza, inactivated, surface antigen
4	B/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type)
	Read more about Influenza, inactivated, surface antigen

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BB02	Influenza, purified antigen	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BB Influenza vaccines
Discover more medicines within J07BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	502620090009907, 502620090010007, 502620090010107
EE	Ravimiamet	1786462, 1800717
ES	Centro de información online de medicamentos de la AEMPS	1181325001
FR	Base de données publique des médicaments	60590648
GB	Medicines & Healthcare Products Regulatory Agency	365091, 365109
IT	Agenzia del Farmaco	047475013, 047475025, 047475037, 047475049
LT	Valstybinė vaistų kontrolės tarnyba	1086875, 1088039, 1088040, 1089826
PL	Rejestru Produktów Leczniczych	100416499